Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Invuity, Inc. | ivty-8k_20160331.htm |
Exhibit 99.1
NEWS RELEASE
INVUITY REPORTS 2016 FIRST QUARTER RESULTS
SAN FRANCISCO, May 5, 2016 - Invuity, Inc. (NASDAQ:IVTY), a leading surgical photonics company, today reported financial results for the first quarter ended March 31, 2016.
Q1 2016 Highlights
|
|
· |
Revenue grew 44% to $6.4 million compared to revenue of $4.4 million in the 2015 first quarter. |
|
|
· |
Gross margin improved to 67% compared to 61% in the 2015 first quarter |
|
|
· |
Approximately 545 hospitals purchased Invuity devices in the first quarter of 2016, up from 410 hospitals in the first quarter of 2015. |
|
|
· |
Approximately 162,000 procedures have been performed using Invuity devices. |
"We are pleased with our first quarter operational and financial results,” said President and CEO Philip Sawyer. “Revenue growth of 44% was achieved through increased surgeon demand for our products and execution from our sales force across our core markets of women’s health, spine/orthopedics and surgical oncology. This has been bolstered by strong interest in our top down Hidden Scar Breast Cancer Surgery marketing programs that will continue to broaden to include additional surgical specialties. Going forward, we expect our new product development pipeline to continue to feed high demand products providing additional leverage for our sales force.”
Financial Results
Revenue was $6.4 million in the first quarter of 2016, compared to $4.4 million in the first quarter of 2015, driven by both an increase in active accounts and an increase in the revenue per active account.
Gross margin for the 2016 first quarter was 67%, compared to 61% for the same period in 2015. Gross margin expansion has been helped by the recent introduction of our non-conductive polymer based retractors, and by overhead efficiencies created as a result of increased sales volumes.
Total operating expenses for the 2016 first quarter were $15.9 million, compared to $10.8 million in the prior year period. We have continued to invest in our commercial platform consistent with our stated objectives, including the continued ramp in sales reps and increased product development efforts related to our new product pipeline.
The net loss for the first quarter of 2016 was $12.1 million, or $0.90 loss per share, compared to a net loss of $9.0 million, or $12.84 loss per share, for the first quarter of 2015. The Company's balance sheet as of March 31, 2016, showed total cash and cash equivalents of $33.9 million.
Invuity's management will discuss the Company's financial results for the first quarter ended March 31, 2016, and provide a general business update during a conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time today, May 5, 2015. To join the live call, participants may dial 1-877-556-8638 (U.S.) or 1-615-247-0174 (International), Conference ID: 96285115. To listen to the live call via Invuity's website, go to www.invuity.com, in the Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call for a period of 90 days in the Events & Presentations section of the website.
About Invuity®
Invuity, Inc. is a medical technology company focused on developing and marketing advanced photonics devices to improve the ability of surgeons to illuminate and visualize the surgical cavity during open minimally invasive and minimal access surgery. The company's patented Intelligent Photonics™ technology enables enhanced surgical precision, efficiency and safety by providing superior visualization. Clinical applications include breast and thyroid oncology, plastic reconstructive, spine, orthopedic, cardiothoracic and general surgery among others. Invuity is headquartered in San Francisco, CA. For more information, visit www.invuity.com.
Forward-Looking Statements
This announcement contains forward-looking statements that involve risks and uncertainties, including statements regarding financial results, future product introductions, future marketing initiatives, market opportunities and potential results from future new initiatives. Actual results could differ materially from those projected in the forward-looking statements as a result of certain risk factors, including, but not limited to: fluctuations in demand or failure to gain market acceptance for the Company's devices; the Company's ability to demonstrate to and gain approval from hospitals to use the Company's devices; the highly competitive business environment for surgical medical devices; the Company's ability to sell its devices at prices that support its current business strategies; difficulty forecasting future financial performance; protection of the Company's intellectual property; and compliance with necessary regulatory clearances or approvals. The Company undertakes no obligation to update the forward-looking information in this release. More information about potential factors that could affect the Company's business and financial results is included in its filings with the Securities and Exchange Commission, including, without limitation, under the captions: "Management's Discussion and Analysis of Financial Condition and Results of Operations," and "Risk Factors," which are on file with the Securities and Exchange Commission.
CONTACT:
Company Contact:
Jim Mackaness
Chief Financial Officer
Invuity, Inc.
415-655-2129
Mark Klausner
Westwicke Partners
443-213-0501
irdept@invuity.com
INVUITY, INC.
Condensed Statements of Operations
(In thousands, except share and per share amounts)
(Unaudited)
|
|
|
Three Months Ended March 31, |
|
|||||
|
|
|
2016 |
|
|
2015 |
|
||
|
Revenue |
|
$ |
6,404 |
|
|
$ |
4,442 |
|
|
Cost of goods sold |
|
|
2,106 |
|
|
|
1,722 |
|
|
Gross profit |
|
|
4,298 |
|
|
|
2,720 |
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
Research and development |
|
|
2,601 |
|
|
|
1,900 |
|
|
Selling, general and administrative |
|
|
13,320 |
|
|
|
8,933 |
|
|
Total operating expenses |
|
|
15,921 |
|
|
|
10,833 |
|
|
Loss from operations |
|
|
(11,623 |
) |
|
|
(8,113 |
) |
|
Interest expense |
|
|
(505 |
) |
|
|
(368 |
) |
|
Interest and other income (expense), net |
|
|
18 |
|
|
|
(551 |
) |
|
Net loss and comprehensive loss |
|
$ |
(12,110 |
) |
|
$ |
(9,032 |
) |
|
Net loss per common share, basic and diluted |
|
$ |
(0.90 |
) |
|
$ |
(12.84 |
) |
|
Weighted-average shares used to compute net loss per common share, basic and diluted |
|
|
13,392,976 |
|
|
|
703,637 |
|
Balance Sheet
as of March 31, 2016 and December 31, 2015
(In thousands, except share and per share amounts)
(Unaudited)
|
|
|
March 31, 2016 |
|
|
December 31, 2015 |
|
||
|
|
|
|
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
33,864 |
|
|
$ |
46,296 |
|
|
Accounts receivable, net |
|
|
4,062 |
|
|
|
3,619 |
|
|
Inventory |
|
|
5,575 |
|
|
|
5,182 |
|
|
Prepaid expenses and other current assets |
|
|
782 |
|
|
|
923 |
|
|
Total current assets |
|
|
44,283 |
|
|
|
56,020 |
|
|
Restricted cash |
|
|
1,090 |
|
|
|
1,090 |
|
|
Property and equipment, net |
|
|
8,955 |
|
|
|
9,195 |
|
|
Total assets |
|
$ |
54,328 |
|
|
$ |
66,305 |
|
|
Liabilities, Convertible Preferred Stock and Stockholders’ Equity |
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
1,765 |
|
|
$ |
2,458 |
|
|
Accrued and other current liabilities |
|
|
4,574 |
|
|
|
4,214 |
|
|
Short-term debt—related party |
|
|
375 |
|
|
|
— |
|
|
Total current liabilities |
|
|
6,714 |
|
|
|
6,672 |
|
|
Deferred rent |
|
|
2,791 |
|
|
|
2,810 |
|
|
Long-term debt—related party |
|
|
14,140 |
|
|
|
14,480 |
|
|
Total liabilities |
|
|
23,645 |
|
|
|
23,962 |
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
Stockholders’ equity : |
|
|
|
|
|
|
|
|
|
Preferred stock, $0.001 par value—10,000,000 shares authorized at March 31, 2016 and December 31, 2015, respectively; no shares issued and outstanding at March 31, 2016 and December 31, 2015 |
|
|
— |
|
|
|
— |
|
|
Common stock, $0.001 par value—100,000,000 shares authorized at March 31, 2016 and December 31, 2015, respectively;13,401,671 and 13,392,358 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively |
|
|
13 |
|
|
|
13 |
|
|
Additional paid-in capital |
|
|
148,387 |
|
|
|
147,937 |
|
|
Accumulated deficit |
|
|
(117,717 |
) |
|
|
(105,607 |
) |
|
Total stockholders’ equity |
|
|
30,683 |
|
|
|
42,343 |
|
|
Total liabilities, convertible preferred stock and stockholders’ equity |
|
$ |
54,328 |
|
|
$ |
66,305 |
|
###